Oneness Biotech Co., Ltd. (TWO.4743) today announced that it has been selected for the first time for inclusion in the S&P Sustainability Yearbook 2023 and awarded the Industry Mover. It is also the first time a pharmaceutical company in Taiwan has been selected for the Sustainability Yearbook. Showing that Oneness’ ESG efforts in implementing corporate governance, protecting environment and promoting social value has been recognized internationally.
Every year S&P Global assesses the sustainability performance of companies around the world from an economic, environmental, and social perspective based on Corporate Sustainability Assessment (CSA) and issues the Sustainability Yearbook. The Sustainability Yearbook 2023 covers 61 industries and over 7,800 companies around the world. To be listed in S&P’s Yearbook, companies must rank in the top 15% of their industry and must achieve a score within 30% of their industry’s top-performing company. In the pharmaceutical industry, only 17 companies were selected for the yearbook, and Oneness is the only one Taiwanese company. The "Industry Mover" award is given to the company with the largest improvement in sustainability performance in each industry. Oneness stands out among the global pharmaceutical industry and has received this honor.
According to the report, Oneness ranks top in the three perspectives: Environmental, Social, and Governance (ESG). Out of the 26 sub-items assessed, 12 ranked in the top 5%, with full scores in product quality management and ethical marketing. Innovation management, supply chain management, and occupational health and safety ranked in the top 3% among the global pharmaceutical industry.
Throughout 2022, Oneness also earned other recognitions for corporate sustainability performance at local and global levels. Oneness has long been promoting gender equality in the workplace and was included in the 2022-2023 Bloomberg Gender Equality Index, the only pharmaceutical company in Taiwan to be selected for two consecutive years. In addition, Oneness has also ranked among Top 5% in the 8th Corporate Governance Evaluation, and the top 10% of listed companies with a market capital of 10 billion TWD or more in the non-finance and non-electronics industry.
Oneness is a pharmaceutical company with focus on R&D, guided by its principles of science, integrity, and transparency. Its core business is the research and development of innovative drugs. Its product, FESPIXON®, a new drug for diabetic foot ulcers, has obtained a drug certificate in Taiwan and is available to low-income patients through a subsidy program. The company has collaborated with international consulting firms and medical associations to provide early access to the drug in unmarketed regions such as the EU and to raise public awareness of diabetes foot care through educational videos and a diabetes foot care website. Responding to climate change, Oneness is committed to reducing its carbon footprint and has completed carbon footprint verification (ISO14067) for FESPIXON, and organizational GHG inventory verification (ISO14064-1). The company plans to use renewable energy and participate in carbon removal projects to further reduce emissions. Oneness will continue to develop innovative world-class drugs while integrating ESG principles into our business strategies and operations to fulfill our corporate social responsibility, maintain a sustainable environment, and create sustainable shared value.
